382TiP - CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)

Thomas Wei ,M.-C Liu,Margarita Reboredo López ,Hope S Rugo ,S.-B Kim,Sara M Tolaney ,Agostina Stradella ,И Н Бондаренко ,Ea Mittendorf ,Mafalda Oliveira ,Michel Pavic ,Yin‐Hsun Feng ,Yann Izarzugaza ,Samuel Guan Wei Ow ,Arlene Chan ,Stew Kroll ,N D'acosta ,Lee S Schwartzberg ,Joseph O’connell ,Joanne L Blum

doi:10.1093/annonc/mdz242.077

382TiP - CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)

Thomas Wei , M.-C Liu + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz242.077

Copy DOI

#Research Grant #Metastatic Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

382TiP - CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)

Full Text